Acumen Pharmaceuticals, Inc.
ABOSNASDAQHealthcare● Active
$2.27
+$0.10(+4.52%)
Market Cap$137386529
P/E Ratio—
52W High$3.6
52W Low$1.05
Acumen Pharmaceuticals, Inc. (ABOS) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ABOS · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.12B) | ($0.10B) | ($0.05B) | ($0.04B) | ($0.10B) |
| Depreciation & Amort. | ($0.00B) | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.01B | $0.01B | $0.01B | $0.00B | $0.00B |
| Change in Working Capital | ($0.01B) | $0.01B | $0.00B | $0.00B | $0.00B |
| Net Cash from Operations | ($0.12B) | ($0.09B) | ($0.04B) | ($0.04B) | ($0.02B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | ($0.04B) | ($0.17B) | ($0.25B) | ($0.04B) | ($0.10B) |
| Sales of Investments | $0.17B | $0.22B | $0.08B | $0.08B | $0.00B |
| Net Cash from Investing | $0.13B | $0.05B | ($0.17B) | $0.04B | ($0.10B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.00B) | ($0.00B) | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | ($0.00B) | $0.03B | $0.00B | $0.00B |
| Net Cash from Financing | ($0.00B) | $0.01B | $0.15B | $0.00B | $0.20B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.12B) | ($0.09B) | ($0.04B) | ($0.04B) | ($0.02B) |
| FCF Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Acumen Pharmaceuticals, Inc. data
About Acumen Pharmaceuticals, Inc. (ABOS) Cash Flow Statement
Acumen Pharmaceuticals, Inc. generated operating cash flow of ($0.12B) and free cash flow of ($0.12B) for 2025 — a FCF margin of —. Capital expenditure was ($0.00B).
Frequently asked questions
ABOS · 4 questionsAcumen Pharmaceuticals, Inc. generated free cash flow of ($0.12B) for 2025, down 34.1% year-over-year.
ABOS free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10